NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/10/2024
Back to search
Official data from USPTO
ALENTIS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
13
Latest update
09/10/2024
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
09/25/2023
Registration date
09/10/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/10/2024
Last transaction
09/10/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
Allschwil, CH
Examiner
KHAN, ASMAT A
Law office
M50
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the literal element "Alentis" where the "A" is in uppercase and in the shape of a stylized triangle and is followed by "lentis" in all lowercase letters.
Holders and representatives
Holders
Alentis Therapeutics AG
Representatives
DERMOT HORGAN IPHORGAN LTD.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical productsfor the treatment of cancerautoimmune diseasesorgan fibrosis; chemical preparations for pharmaceutical or medical purposesfor the treatment of cancerautoimmune diseasesorgan fibrosis; biological preparations for medical and therapeutic use for the treatment of cancerautoimmune diseasesorgan fibrosis; all the aforesaid goods not for ophthalmological use; biopharmaceutical productspharmaceutical preparations for cancer treatment; pharmaceutical preparations and substances for cancer treatment; pharmaceutical preparations and substances for cancer prevention
Publications
History of USPTO decisions and trademark events.
13 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/10/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/25/2024
PUBO
PUBLISHED FOR OPPOSITION
06/25/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/05/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/17/2024
DOCK
ASSIGNED TO EXAMINER
05/16/2024
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
02/22/2024
ALIE
ASSIGNED TO LIE
02/22/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/11/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/10/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
10/01/2023
NWAP
NEW APPLICATION ENTERED
09/28/2023
Continuous trademark protection
Get notified about every new filing that threatens ALENTIS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.